BioNTech's Oncology Ambitions Fuel Stock Surge Amid Analyst Debate

BioNTech shares surge over 8% as promising Phase 2 data for its cancer drug BNT323 outperforms chemo. The stock tests a key technical level amid a strategic pivot from COVID vaccines.

BioNTech shares have rallied over 8% in the past week, buoyed by compelling clinical data for a key cancer drug candidate. The stock, trading at 84.55 EUR, is now testing a key technical level at its 50-day moving average of 84.60 EUR. This investor optimism stems from a pivotal oncology program that is charting a clear course toward regulatory submission, even as the company navigates a significant financial transition away from its COVID-19 vaccine business.

The catalyst is the Phase 2 data for trastuzumab pamirtecan (BNT323/T-Pam), an antibody-drug conjugate developed with partner DualityBio. In patients with advanced endometrial cancer, the therapy demonstrated an objective response rate of 47.9% and a median progression-free survival of 8.1 months. These figures starkly outperform standard chemotherapy, which typically yields response rates around 15% and progression-free survival of approximately four months. The drug already holds Fast-Track and Breakthrough Therapy designations from the U.S. FDA, streamlining the path forward.

Wall Street's reaction to this data package has been mixed, revealing a split in analyst sentiment. Bank of America Securities raised its price target to $130 from $128, maintaining a "Buy" rating, and highlighted the potential approval as a foundation for building commercial oncology infrastructure. Morgan Stanley made a minor upward adjustment, increasing its target to $126 from $125 with an "Overweight" rating. Berenberg Bank reaffirmed its buy recommendation.

A contrasting view came from Leerink Partners, which slashed its price target to $94 from $113, citing reduced prospects for a separate pipeline asset, the CTLA-4 candidate gotistobart, in an ongoing lung cancer study.

Financially, BioNTech is well-positioned to fund its strategic shift. The company anticipates a roughly 25% revenue decline in 2026 to between 2.0 and 2.3 billion EUR as its COVID-19 vaccine business winds down as planned. Concurrently, it plans substantial investment, with adjusted R&D expenses projected to reach 2.2 to 2.5 billion EUR. A robust liquidity cushion of 17.2 billion EUR provides ample security for this transformation.

The coming weeks are critical for corporate governance. On May 15, the virtual Annual General Meeting will see shareholders vote on expanding the supervisory board from six to eight members. The proposed new additions are specialists in oncology and clinical development. Market observers also await clarity on the ongoing search for a new CEO, a process that has previously weighed on the stock price.

Further near-term focus falls on the first-quarter earnings report scheduled for May 5. The AGM will also decide on creating new authorized capital of up to 129.5 million EUR. Management has been clear that the oncology pipeline will not generate commercial revenue in 2026. However, the planned Biologics License Application (BLA) submission for BNT323 this year represents a fundamental shift, marking BioNTech's transition from pure research into commercial cancer medicine.